911010-88-3

Usage

Uses

Used in Pharmaceutical Industry:
5-Amino-1-benzyl-1,2,3,6-tetrahydro-pyridine-4-carboxylic acid ethyl ester is used as a potential therapeutic agent for neurological disorders due to its pharmacological properties that may contribute to the treatment and management of such conditions.
Used in Oncology Research:
In the field of oncology, 5-Amino-1-benzyl-1,2,3,6-tetrahydro-pyridine-4-carboxylic acid ethyl ester is being studied for its potential as an anticancer agent. Its specific mechanisms of action in inhibiting or slowing down the growth of cancer cells are still under investigation, with the aim of identifying its potential role in cancer treatment.
Used in Drug Development:
As a chemical compound with promising pharmacological properties, 5-Amino-1-benzyl-1,2,3,6-tetrahydro-pyridine-4-carboxylic acid ethyl ester is utilized in drug development research to explore its therapeutic applications and to understand its mechanisms of action, which may lead to the creation of new medications for various diseases.

Upstream product

• 39514-19-7 ethyl 1-benzyl-3-oxo-4-piperidinecarboxylate 
• 52763-21-0 ethyl 1-benzyl-3-oxopiperidine-4-carboxylate hydrochloride 

Downstream Products

• 911010-89-4 methyl 7-benzyl-4-hydroxy-5,6,7,8-tetrahydro-1,7-naphthyridine-3-carboxylate 

Relevant academic research and scientific papers

Heterocyclic compound, pharmaceutical composition and application

The invention discloses a heterocyclic compound which is a heterocyclic compound shown as a formula I, a pharmaceutically acceptable salt, a stereoisomer, a tautomer, a hydrate, a solvate, a metabolite or a prodrug thereof. The heterocyclic compound can be used for preparing medicines for treating and/or preventing cancers related to KRAS G12C mutation. The invention also discloses a pharmaceutical composition containing the heterocyclic compound, and application of the compound shown in the formula I, or pharmaceutically acceptable salt, stereoisomer, tautomer, hydrate, solvate, metabolite, prodrug or pharmaceutical composition thereof in preparation of drugs.

KRAS MUTANT PROTEIN INHIBITORS

The invention relates to a KRAS mutant protein inhibitor, a composition containing the inhibitor and the use thereof.

Fused cyanopyridine compound and preparation method and application thereof

The invention discloses a fused cyanopyridine compound shown as a general formula I-1 or I-2, or a pharmaceutically acceptable salt thereof, or an enantiomer, a diastereoisomer, a tautomer, a torsional isomer, a solvate, a polymorphic substance or a prodrug thereof, and a preparation method and a pharmaceutical application of the fused cyanopyridine compound, wherein the definition of each group is shown in the specification.

Saturated six-membered ring heterocyclic compound as well as preparation method and application thereof

The invention discloses a saturated six-membered ring heterocyclic compound as well as a preparation method and application thereof. The invention discloses a saturated six-membered ring heterocycliccompound shown as a general formula I, or pharmaceutically acceptable salt thereof, or an enantiomer, a diastereoisomer, a tautomer, a torsional isomer, a solvate, a polymorphic substance or prodrug thereof, as well as a preparation method and a pharmaceutical application of the saturated six-membered ring heterocyclic compound. The definition of each group is as described in the specification.

Design, synthesis and biological evaluations of N-Hydroxy thienopyrimidine-2,4-diones as inhibitors of HIV reverse transcriptase-associated RNase H

Human immunodeficiency virus (HIV) reverse transcriptase (RT) associated ribonuclease H (RNase H) is the only HIV enzymatic function not targeted by current antiviral drugs. Although various chemotypes have been reported to inhibit HIV RNase H, few have s

TRKA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF

The present invention is directed to six membered heteroaryl benzamide compounds of formula (I), which are tropomyosin-related kinase (Trk) family protein kinase inhibitors, and hence are useful in the treatment of pain, inflammation, cancer, restenosis, atherosclerosis, psoriasis, thrombosis, a disease, disorder, injury, or malfunction relating to dysmyelination or demyelination or a disease or disorder associated with abnormal activities of nerve growth factor (NGF) receptor TrkA.

Selection, synthesis, and structure-activity relationship of tetrahydropyrido[4,3-d]pyrimidine-2,4-diones as human GnRH receptor antagonists

The present article describes a selection of a new class of small molecule antagonists for the h-GnRH receptor, their preparation, and evaluation in vitro. Three computational methods were combined into a consensus score, to rank order virtual templates. The top 5% of templates were further evaluated in silico and assessed for novelty and synthetic accessibility. The tetrahydropyrido[4,3-d]pyrimidine-2,4-dione core was selected for synthesis and evaluated in vitro. Using an array approach for analog design and synthesis, we were able to drive the binding below 10 nM for the h-GnRH receptor after two rounds of optimization.

Bicycloheteroaryl compounds as P2X7 modulators and uses thereof

Bicycloheteroaryl compounds are disclosed that have a formula represented by the following: The compounds may be prepared as pharmaceutical compositions, and may be used for the prevention and treatment of a variety of conditions in mammals including huma